Abstract

Amyloid aggregation has been related to an increasing number of human illnesses, from Alzheimer’s and Parkinson’s diseases (AD/PD) to Creutzfeldt-Jakob disease. Commonly, only prions have been considered as infectious agents with a high capacity of propagation. However, recent publications have shown that many amyloid proteins, including amyloid β-peptide, α-synuclein (α-syn) and tau protein, also propagate in a “prion-like” manner. Meanwhile, no link between propagation of pathological proteins and neurotoxicity has been demonstrated. The extremely low infectivity under natural conditions of most non-prion amyloids is far below the capacity to spread exhibited by prions. Nonetheless, it is important to elucidate the key factors that cause non-prion amyloids to become infectious agents. In recent years, important advances in our understanding of the amyloid processes of amyloid-like proteins and unrelated prions (i.e., yeast and fungal prions) have yielded essential information that can shed light on the prion phenomenon in mammals and humans. As shown in this review, recent evidence suggests that there are key factors that could dramatically modulate the prion capacity of proteins in the amyloid conformation. The concentration of nuclei, the presence of oligomers, and the toxicity, resistance and localization of these aggregates could all be key factors affecting their spread. In short, those factors that favor the high concentration of extracellular nuclei or oligomers, characterized by small size, with a low toxicity could dramatically increase prion propensity; whereas low concentrations of highly toxic intracellular amyloids, with a large size, would effectively prevent infectivity.

Highlights

  • Many neurodegenerative diseases are characterized by the aggregation of misfolded proteins in the brain, the so-called amyloids

  • Amyloid fibrillogenesis is a nucleation-dependent process which depends on protein concentration and can be promoted or triggered by homologous preformed amyloids that act as templates in a mechanism known as seeding (Jarrett and Lansbury, 1993; Chiti and Dobson, 2006)

  • Not yet proven in mammal and human prions, fibril resistance to denaturation could be a key factor in the fragmentation of amyloids

Read more

Summary

INTRODUCTION

Many neurodegenerative diseases are characterized by the aggregation of misfolded proteins in the brain, the so-called amyloids. Direct crossing of the blood barrier (Banks et al, 2009), dissemination via astrocytes and fibroblasts (Hollister et al, 2015), infection by inducing microglia recruitment (Baker et al, 2002; Marella and Chabry, 2004; Pearce et al, 2015; Tu et al, 2015) or spreading via immune system cells (Isaacs et al, 2006; Bradford and Mabbott, 2012) represent other potential spreading mechanisms

NUMBER OF AMASSED NUCLEI
AGGREGATE SIZE AND SPREADING CAPACITY
TOXICITY OF AMYLOID AGGREGATES
AMYLOID RESISTANCE
AMYLOID LOCATION
CONCLUDING REMARKS

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.